Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1972 | 1 |
2016 | 1 |
2017 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
dorogova n
(46 results)?
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.
N Engl J Med. 2017.
PMID: 28002679
Free article.
Clinical Trial.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators.
Steinman L, et al.
N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904.
N Engl J Med. 2022.
PMID: 36001711
Clinical Trial.
Item in Clipboard
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group.
Montalban X, et al.
N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10.
N Engl J Med. 2019.
PMID: 31075187
Clinical Trial.
Item in Clipboard
[Pulmonary adenomatosis].
Daniliak IG, Dorogov NI, Guliaeva FE, Laskavyi IS.
Daniliak IG, et al. Among authors: dorogov ni.
Sov Med. 1972 Apr;35(4):134-7.
Sov Med. 1972.
PMID: 4351023
Russian.
No abstract available.
Item in Clipboard
RETRACTED ARTICLE: Compliance as a Cost-Effective System of Interaction Between Business and Government.
Dorogov NI, Kapitonov IA, Batyrova NT.
Dorogov NI, et al.
J Bus Ethics. 2021;174(2):485. doi: 10.1007/s10551-021-04890-5. Epub 2021 Jul 12.
J Bus Ethics. 2021.
PMID: 34276112
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite